BRAF protein is a serine/threonine kinase with 766 amino acids. Approximately 15% of human cancers harbor BRAF mutations as well as other BRAF anomalies (amplifications, fusions). Somatic mutations mainly occur in the catalytic kinase domain (CR3), and the predominant mutation is p.V600E which is the substitution of glutamic acid (E) for valine (V) as result of a mutation at codon 600 of the kinase domain. To our knowledge, the vast majority of the cancers have non-germline BRAF mutations. Here we describe a case of a 60-year-old female with a history of hairy cell leukemia (HCL) who presented with aphasia and forgetfulness. A follow-up Brain CT scan showed three distinct brain lesions which were found to be diagnostic of melanoma (confirmed by immunohistochemistry) with no evidence of a concurrent brain involvement by a B-cell neoplasm. Molecular studies confirmed the same BRAF p.V600E mutation in both malignancies (hairy cell leukemia and melanoma). Thereafter the patient was started on BRAF inhibitor treatment and is now symptom-free after one year of follow up. Having two concurrent malignancies with a shared BRAF mutation is extremely rare and makes this an excellent example of a genomic marker-driven treatment in two histologically and immunophenotypically distinct tumors.
SithanandamG, DruckT, CannizzaroLA, LeuzziG, HuebnerK, RappUR. B-raf and a B-raf pseudogene are located on 7q in man. Oncogene. 1992;7(4):795-9. [PMID:1565476]
BlachlyJS, LozanskiG, LucasDM, GreverMR, KendraK, AndritsosLA. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib. J Natl Compr Canc Netw. 2015;13(1):9-13, quiz 13. [PMID:25583765] [https://doi.org/10.6004/jnccn.2015.0004].
SithanandamG, KolchW, DuhFM, RappUR. Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene. 1990;5(12):1775-80. [PMID:2284096]
TanamiH, ImotoI, HirasawaA, et al. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene. 2004;23(54):8796-804. [PMID:15467732] [https://doi.org/10.1038/sj.onc.1208152].
RossJS, WangK, ChmieleckiJ, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2016;138(4):881-90. [PMID:26314551] [https://doi.org/10.1002/ijc.29825].
SarkozyA, CartaC, MorettiS, et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat. 2009;30(4):695-702. [PMID:19206169] [https://doi.org/10.1002/humu.20955].
ChapmanPB, HauschildA, RobertC, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16. [PMID:21639808] [https://doi.org/10.1056/NEJMoa1103782].
DietrichS, GlimmH, AndrulisM, von KalleC, HoAD, ZenzT. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366(21):2038-40. [PMID:22621641] [https://doi.org/10.1056/NEJMc1202124].
HauschildA, GrobJ-J, DemidovLV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomized controlled trial. Lancet. 2012;380(9839):358-65. [PMID:22735384] [https://doi.org/10.1016/S0140-6736(12)60868-X].
PrahalladA, SunC, HuangS, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100-3. [PMID:22281684] [https://doi.org/10.1038/nature10868].
CorcoranRB, AtreyaCE, FalchookGS, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol. 2015;33(34):4023-31. [PMID:26392102] [https://doi.org/10.1200/JCO.2015.63.2471].
TurskiML, VidwansSJ, JankuF, et al. Genomically driven tumors and actionability across histologies: BRAF-Mutant cancers as a paradigm. Mol Cancer Ther. 2016;15(4):533-47. [PMID:27009213] [https://doi.org/10.1158/1535-7163.MCT-15-0643].
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email